Developer docs
API playgroundTry for free, no card

Search company profiles

Aditum Bio

Full company profile

uuid0002ag8

Namestring
Aditum Bio
Legal namestring
Aditum Bio Management Company, LLC
Websiteurl
aditumbio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Aditum Bio is a privately held biotech venture capital firm founded in 2019 and headquartered at 1111 Broadway Suite 1300 in Oakland, California. The firm operates a distinctive "spin-out incubator" model: it identifies and in-licenses clinic-ready or translational-stage drug candidates from large pharmaceutical and biotech companies (including Novartis, Sosei Heptares, Daewoong Pharmaceutical, Inmagene Biopharmaceuticals, Taisho Pharmaceutical, vTv Therapeutics, Motorpharma, Leads Biolabs, and Mabwell Bioscience), then launches a dedicated portfolio company under the Aditum umbrella to advance each asset through Phase 1 and Phase 2 clinical trials. Each portfolio company runs with its own dedicated leadership team augmented by Aditum's in-house R&D, nonclinical pharmacology, CMC, regulatory affairs, and clinical operations experts, and shares tech-enabled clinical trial execution infrastructure via a partnership with TrialSpark as well as digital patient engagement tools (mobile applications) to support adherence during treatment. Since inception, Aditum has launched 13 portfolio companies spanning obesity, substance use disorders, treatment-resistant depression, renal disease, antivirals, spasticity, autoimmune and inflammatory disorders, and cardiovascular disease.

Aditum's revenue model is hybrid: it deploys institutional LP capital through three sequential venture funds (Fund I launched 2019 at $133M per SEC filings; Fund II launched 2021; Fund III launched 2024 and currently deploying) generating management fees and, on exit, carried interest; it also captures licensing royalties and milestone payments through equity stakes in portfolio companies, with disclosed deal economics ranging from $35M upfront plus $579M milestones (Oblenio/Leads Biolabs) to up to $1B total (Kalexo/Mabwell) and up to $362.50M plus milestones and royalties (Clavis Bio/Fosun Pharma). The go-to-market is relationship-driven and partnership-led: deal flow originates through direct outreach to academic institutions and pharma licensors, while global commercialization is enabled via strategic pharma partners — for example, a five-year collaboration with Shanghai-based Fosun Pharma (announced December 2025) grants Fosun exclusive development, manufacturing, and commercialization rights in China, Hong Kong, and Macau for Clavis Bio programs, with Aditum launching additional subsidiaries for any programs Clavis advances.

The firm has demonstrated its model with a landmark exit — Eli Lilly's August 2023 acquisition of portfolio company Versanis Bio (founded and seeded by Aditum to develop bimagrumab for obesity) for up to $1.925 billion in cash inclusive of milestones — and has continued to scale portfolio company financings, including a $70 million Series B for Tempero Bio (March 2025, led by 8VC) and a $62 million oversubscribed Series B for Oblenio Bio (June 2026, led by Pfizer Ventures). Co-founded by former Novartis CEO Joe Jimenez and former NIBR President Dr. Mark Fishman, Aditum positions itself as serving institutional LPs seeking exposure to de-risked translational-stage biotech opportunities, pharma licensors seeking monetization of deprioritized assets, and patients in underserved disease populations neglected by large pharma and biotech VC funds.

Short descriptiontext

Aditum Bio is a privately held biotech venture capital firm founded in 2019 that in-licenses translational-stage drug candidates from large pharma, spins out dedicated portfolio companies under its umbrella, and advances them through Phase 1/Phase 2 trials across 13 companies, serving institutional LPs and pharmaceutical licensors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOakland, United States
HQ citystring
Oakland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech venture capital, pharmaceutical asset acquisition, drug development partnerships, translational-stage investment, biotech incubator model
Industry1 code
PRIMARYFSANAHAK
Corporate Fintech / Insurtech CVC (Financial-services-led CVC)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biotech Venture Capital
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Biotech venture capital fund returns (Fund I, Fund II, Fund III)
TypeManaged Services
Description

Aditum Bio generates returns by deploying capital from its venture funds (Fund I launched 2019, Fund II launched 2021, Fund III launched 2024) into in-licensed drug candidates, then spinning out individual portfolio companies dedicated to advancing each candidate through Phase 1/Phase 2 trials. Revenue comes from management fees on committed capital and carried interest / equity upside when portfolio companies are sold or go public (e.g., Versanis Bio sold to Eli Lilly for $1.925 billion in August 2023).

aditumbio.com
2Licensing royalties and milestones from portfolio companies
TypeLicensing Royalties
Description

Through equity stakes in and licensing arrangements with portfolio companies, Aditum Bio is eligible for milestone payments and royalties tied to clinical and commercial advancement of in-licensed assets. Example: Oblenio Bio's agreement with Leads Biolabs includes up to $35M upfront and near-term payments plus $579M in development, regulatory, and commercialization milestones and royalties on sales; Kalexo Bio deal with Mabwell includes up to USD $1 billion total in upfront/milestone payments plus tiered royalties on global sales.

aditumbio.com
3Strategic pharma partnership economics
TypeLicensing Royalties
Description

Aditum Bio negotiates strategic deals with global pharma partners for regional development and commercialization rights to assets advanced through portfolio companies — e.g., the Clavis Bio five-year collaboration with Fosun Pharma provides potential payments to Fosun of up to $362.50 million plus milestones and royalties, with Aditum launching additional subsidiaries for any programs Clavis advances.

fiercebiotech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Fund I — Launched 2019 (closed at $133M); Fund II — Launched 2021; Fund III — Launched 2024 (currently deploying). Fund sizes and LP terms not publicly disclosed.
ModelOther
Notes

Fund commitment terms, management fees, and carried interest are not publicly disclosed; Fund I closed at $133,040,000 according to SEC filings referenced in news coverage.

aditumbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Aditum Bio is a biotech venture capital firm that identifies, in-licenses, and acquires clinic-ready or translational-stage drug candidates from large pharmaceutical companies, then spins out dedicated portfolio companies under the Aditum umbrella to advance each candidate through Phase 1 and Phase 2 clinical trials. The firm operates through successive venture funds (Fund I launched 2019, Fund II launched 2021, Fund III launched 2024) and has launched 13 portfolio companies targeting underserved disease areas including obesity, depression, substance use disorders, renal disease, infectious diseases, autoimmune and cardiovascular disorders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 12 values shown
  • 13 portfolio companies launched since 2019
+11 more records
Product and service4 records
1Aditum Bio Fund I
CategoryInvestment fund
2Aditum Bio Fund II
CategoryInvestment fund
3Aditum Bio Fund III
CategoryInvestment fund
4Aditum Bio Biotech Venture Capital Platform
CategoryCore offering
Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierFlagship Regional PartnershipTypeStrategic or Co-development PartnerAnnounced on2025-12-19
Description

Five-year collaboration with newly launched portfolio company Clavis Bio: Fosun holds exclusive rights to develop, manufacture and commercialize partnered assets in China, Hong Kong and Macau, while Clavis Bio can license programs elsewhere. Potential payments to Fosun of up to $362.50 million plus milestones and royalties. Aditum will launch additional subsidiaries for any programs Clavis advances, with Fosun receiving a minority stake in these new companies.

Strategic tierFlagship / Core Portfolio PartnershipTypeStrategic or Co-development PartnerAnnounced on2025-09-17
Description

Exclusive global license agreement in conjunction with formation of Kalexo Bio (portfolio company) to develop 2MW7141, a novel dual-target siRNA candidate for lipid management in dyslipidemia and prevention of high-risk atherosclerotic cardiovascular disease (ASCVD) events. Mabwell granted exclusive worldwide rights to develop, manufacture, and commercialize 2MW7141; Mabwell is eligible for up to USD $1 billion total in upfront and milestone payments plus tiered royalties on global sales, including $12 million in non-refundable upfront and near-term cash payments and an equity stake in Kalexo Bio. Aditum Bio will provide funding for Kalexo Bio.

3Leads Biolabs (Nanjing Leads Biolabs Co., Ltd.)
Strategic tierFlagship / Core Portfolio PartnershipTypeStrategic or Co-development PartnerAnnounced on2024-11-07
Description

Strategic asset licensing and co-development partnership: Leads Biolabs granted Oblenio Bio (an Aditum Bio portfolio company, the thirteenth launched) an exclusive option to develop, manufacture, and commercialize LBL-051, a first-in-class CD19×BCMA×CD3 tri-specific T-cell engager antibody for autoimmune diseases, worldwide. Leads Biolabs is eligible for up to $35M in upfront and near-term payments plus $579M in development, regulatory, and commercialization milestone payments, royalties on sales, and an equity stake in Oblenio Bio. The compound was discovered using Leads Biolabs' proprietary LeadsBody™ platform. In June 2026 Oblenio closed a $62M oversubscribed Series B led by Pfizer Ventures with Aditum participation to advance LBL-051 into clinical development.

aditumbio.com
4Inmagene Biopharmaceuticals
Strategic tierMajor Portfolio Asset LicensorTypeStrategic or Co-development PartnerAnnounced on2023-09-21
Description

Asset in-licensing partnership in conjunction with formation of Celexor Bio (tenth Aditum Bio company): Inmagene licensed IMG-018, a depleting antibody targeting immunoglobulin-like transcript 7 (ILT7) on plasmacytoid dendritic cells (pDCs), renamed CLXR-901, for autoimmune and inflammatory disorders.

aditumbio.com
Strategic tierMajor Exit / Strategic AcquirerTypeStrategic or Co-development PartnerAnnounced on2023-08-14
Description

Strategic acquirer of Versanis Bio (portfolio company founded/seeded by Aditum Bio) for up to $1.925 billion in cash, inclusive of upfront payment and subsequent milestone payments, expanding Lilly's cardiometabolic portfolio to include bimagrumab.

Strategic tierMajor Portfolio Asset LicensorTypeStrategic or Co-development PartnerAnnounced on2023-04-27
Description

Asset in-licensing partnership in conjunction with formation of Vitalli Bio (ninth Aditum Bio company): Daewoong licensed a highly selective dual inhibitor of Interleukin-2-Inducible T-Cell Kinase (ITK) and Bruton's Tyrosine Kinase (BTK), renamed VIT-801, anticipated to enter Phase 1 studies in 2023. Vitalli Bio also granted an option to license earlier stage dual-target inhibitors in development by Daewoong.

7Motorpharma, Ltd. (Hungary)
Strategic tierMajor Portfolio Asset LicensorTypeStrategic or Co-development PartnerAnnounced on2021-11-15
Description

Asset in-licensing partnership in conjunction with formation of Motric Bio (seventh Aditum Bio company): Motorpharma licensed a myosin-2 inhibitor that has shown selective inhibition of fast skeletal muscle, to develop a therapy for spasticity associated with neurological injuries and disease (stroke, multiple sclerosis, etc.). Motorpharma is a spin-off of Eötvös Loránd University, Hungary.

aditumbio.com
Strategic tierFoundational / Repeated Asset LicensorTypeStrategic or Co-development PartnerAnnounced on2021-09-07
Description

Recurring asset licensing counterparty: Via Nova Therapeutics was founded in August 2021 following the in-licensing of four preclinical antiviral programs (influenza A, human rhinovirus, BK polyomavirus, adenovirus) from Novartis. Aditum Bio also licensed bimagrumab from Novartis (the foundation for Versanis Bio, sold to Eli Lilly for up to $1.925B in August 2023). Additional portfolio asset licensors include Celexor Bio/Inmagene (co-developing IMG-020 izokibep).

9Taisho Pharmaceutical Co., Ltd.
Strategic tierMajor Portfolio Asset LicensorTypeStrategic or Co-development PartnerAnnounced on2021-06-30
Description

Asset licensing partnership: Taisho Pharmaceutical in-licensed ANC-501, a selective vasopressin 1b receptor (V1b) antagonist, to Aditum Bio's portfolio company Ancora Bio (later renamed EmbarkNeuro) for the treatment of treatment-resistant depression. The asset is a Phase II-ready, first-in-class V1b receptor antagonist that entered Phase 2 trials in November 2022.

aditumbio.com
10TrialSpark
Strategic tierCore Operating PartnerTypeTechnology or IntegrationAnnounced on2021-06-30
Description

Technology-driven clinical trial execution partner: TrialSpark operates as an alternative to traditional CROs, with a digital platform that optimizes all aspects of a clinical trial, enabling faster trial completion, higher data quality, and a more patient-centric experience. Aditum Bio uses TrialSpark to complete clinical trials faster and at lower cost than traditional trials; TrialSpark partners with doctors in community settings to create trial and referral sites within their existing practices, accelerating recruitment rates.

aditumbio.com
Strategic tierMajor Portfolio Asset LicensorTypeStrategic or Co-development PartnerAnnounced on2020-12-15
Description

Asset in-licensing partnership in conjunction with formation of Anteris Bio (third Aditum Bio company): vTv Therapeutics licensed ANT-401, a small molecule activator of Nrf2 (via Bach1 inhibition), for the treatment of renal disease.

12Sosei Heptares (4565:JP)
Strategic tierMajor Portfolio Asset LicensorTypeStrategic or Co-development PartnerAnnounced on2020-11-02
Description

Asset licensing partnership: TMP-301 (mGluR5 negative allosteric modulator for substance use disorders and anxiety) was in-licensed from Sosei Heptares to form Tempero Bio, Aditum's second portfolio company. Sosei Heptares is Japan-listed; its StaR®/SBDD platform underpins the asset. Tempero Bio subsequently received FDA IND clearance (Jan 2023) and a $5.3M NIDA grant, and closed a $70M Series B in March 2025.

aditumbio.com
13Paul Sekhri (co-founder, eGenesis Inc.)
Strategic tierFounding Team Member (Advisory)TypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Co-founder of Aditum Bio alongside Joe Jimenez and Mark Fishman; President and CEO of eGenesis Inc., who remained at eGenesis but contributed to the formation of the firm in 2019.

aditumbio.com
Recent move17 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BridgeBio is an asset-centric biotech that licenses and develops genetically validated therapies across multiple therapeutic areas, similarly spinning out focused subsidiaries. The 'asset-first, company-second' operating philosophy closely mirrors Aditum's incubator approach.

TypeDirect peer
Description

Atlas Venture is a leading early-stage biotech VC firm that co-led the $70M Series A for Aditum's Versanis Bio. It is a direct strategic peer with a comparable company-creation approach focused on building therapeutic-area-focused biotechs from inception.

TypeDirect peer
Description

Forbion is a leading European biotech VC with a strong company-creation and late-stage growth practice. It is comparable to Aditum in deploying capital into translational-stage biotechs and building dedicated companies around de-risked assets.

TypeDirect peer
Description

Medicxi is a European asset-centric biotech VC firm that co-led the $70M Series A for Aditum's Versanis Bio. It is one of the most direct strategic peers in the asset-centric biotech VC space, with comparable fund sizes and a similar translational-stage focus.

TypeBroad incumbent
Description

Khosla Ventures is a large generalist VC firm with a significant biotech practice that co-invested in Aditum's Tempero Bio ($70M Series B in March 2025). It is a broader incumbent in the biotech VC space with adjacent translational-stage exposure.

TypeBroad incumbent
Description

ARCH is a large, established biotech VC firm with a long track record in company formation. It represents a broader incumbent peer in the translational-stage biotech VC space, though with a wider therapeutic-area mandate and significantly larger AUM.

TypeEmerging player
Description

Curie.Bio is a newer biotech VC firm offering 'founder-friendly' asset incubation, with overlap in translational-stage deal sourcing and shared operating infrastructure. It represents a more recent entrant with a similar company-creation model.

TypeDirect peer
Description

Roivant operates a near-identical 'Vant' model of in-licensing deprioritized pharma assets and spinning out dedicated subsidiaries to advance them. Both firms use translational-stage sourcing, dedicated portfolio companies, and shared in-house operating infrastructure, making Roivant the closest public-market comparable to Aditum's spin-out model.

TypeBroad incumbent
Description

OrbiMed is one of the largest healthcare-dedicated investment firms globally, with broad public and private biotech exposure. It is a broader incumbent in the biotech VC space, offering partial overlap with Aditum's translational-stage deployment model but at materially greater AUM scale.

10Cydan Development
TypeDirect peer
Description

Cydan is an asset-creation biotech incubator that identifies promising therapeutic assets and spins out dedicated companies to develop them, mirroring Aditum's model with a sharper focus on rare diseases. Operates a near-identical in-license-and-spin-out framework.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries12 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment5 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aditum Bio

Biotech Venture Capitaladitumbio.com

Aditum Bio is a privately held biotech venture capital firm founded in 2019 that in-licenses translational-stage drug candidates from large pharma, spins out dedicated portfolio companies under its umbrella, and advances them through Phase 1/Phase 2 trials across 13 companies, serving institutional LPs and pharmaceutical licensors.

What Aditum Bio does

Aditum Bio is a privately held biotech venture capital firm founded in 2019 and headquartered at 1111 Broadway Suite 1300 in Oakland, California. The firm operates a distinctive "spin-out incubator" model: it identifies and in-licenses clinic-ready or translational-stage drug candidates from large pharmaceutical and biotech companies (including Novartis, Sosei Heptares, Daewoong Pharmaceutical, Inmagene Biopharmaceuticals, Taisho Pharmaceutical, vTv Therapeutics, Motorpharma, Leads Biolabs, and Mabwell Bioscience), then launches a dedicated portfolio company under the Aditum umbrella to advance each asset through Phase 1 and Phase 2 clinical trials. Each portfolio company runs with its own dedicated leadership team augmented by Aditum's in-house R&D, nonclinical pharmacology, CMC, regulatory affairs, and clinical operations experts, and shares tech-enabled clinical trial execution infrastructure via a partnership with TrialSpark as well as digital patient engagement tools (mobile applications) to support adherence during treatment. Since inception, Aditum has launched 13 portfolio companies spanning obesity, substance use disorders, treatment-resistant depression, renal disease, antivirals, spasticity, autoimmune and inflammatory disorders, and cardiovascular disease.

Aditum's revenue model is hybrid: it deploys institutional LP capital through three sequential venture funds (Fund I launched 2019 at $133M per SEC filings; Fund II launched 2021; Fund III launched 2024 and currently deploying) generating management fees and, on exit, carried interest; it also captures licensing royalties and milestone payments through equity stakes in portfolio companies, with disclosed deal economics ranging from $35M upfront plus $579M milestones (Oblenio/Leads Biolabs) to up to $1B total (Kalexo/Mabwell) and up to $362.50M plus milestones and royalties (Clavis Bio/Fosun Pharma). The go-to-market is relationship-driven and partnership-led: deal flow originates through direct outreach to academic institutions and pharma licensors, while global commercialization is enabled via strategic pharma partners — for example, a five-year collaboration with Shanghai-based Fosun Pharma (announced December 2025) grants Fosun exclusive development, manufacturing, and commercialization rights in China, Hong Kong, and Macau for Clavis Bio programs, with Aditum launching additional subsidiaries for any programs Clavis advances.

The firm has demonstrated its model with a landmark exit — Eli Lilly's August 2023 acquisition of portfolio company Versanis Bio (founded and seeded by Aditum to develop bimagrumab for obesity) for up to $1.925 billion in cash inclusive of milestones — and has continued to scale portfolio company financings, including a $70 million Series B for Tempero Bio (March 2025, led by 8VC) and a $62 million oversubscribed Series B for Oblenio Bio (June 2026, led by Pfizer Ventures). Co-founded by former Novartis CEO Joe Jimenez and former NIBR President Dr. Mark Fishman, Aditum positions itself as serving institutional LPs seeking exposure to de-risked translational-stage biotech opportunities, pharma licensors seeking monetization of deprioritized assets, and patients in underserved disease populations neglected by large pharma and biotech VC funds.

Aditum Bio firmographics

Firmographics
Name
Aditum Bio
Legal name
Aditum Bio Management Company, LLC
Website
https://aditumbio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Aditum Bio is a privately held biotech venture capital firm founded in 2019 that in-licenses translational-stage drug candidates from large pharma, spins out dedicated portfolio companies under its umbrella, and advances them through Phase 1/Phase 2 trials across 13 companies, serving institutional LPs and pharmaceutical licensors.
Ownership category
akta.pro rank

Aditum Bio industry classification

Industry
Product category
Biotech Venture Capital
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYFSANAHAK
Corporate Fintech / Insurtech CVC (Financial-services-led CVC)

Keywords

  • Biotech venture capital
  • Pharmaceutical asset acquisition
  • Drug development partnerships
  • Translational-stage investment
  • Biotech incubator model

Where Aditum Bio is headquartered

Location

Headquarters

HQ city
Oakland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aditum Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biotech venture capital fund returns (Fund I, Fund II, Fund III): Aditum Bio generates returns by deploying capital from its venture funds (Fund I launched 2019, Fund II launched 2021, Fund III launched 2024) into in-licensed drug candidates, then spinning out individual portfolio companies dedicated to advancing each candidate through Phase 1/Phase 2 trials. Revenue comes from management fees on committed capital and carried interest / equity upside when portfolio companies are sold or go public (e.g., Versanis Bio sold to Eli Lilly for $1.925 billion in August 2023).
  2. Licensing royalties and milestones from portfolio companies: Through equity stakes in and licensing arrangements with portfolio companies, Aditum Bio is eligible for milestone payments and royalties tied to clinical and commercial advancement of in-licensed assets. Example: Oblenio Bio's agreement with Leads Biolabs includes up to $35M upfront and near-term payments plus $579M in development, regulatory, and commercialization milestones and royalties on sales; Kalexo Bio deal with Mabwell includes up to USD $1 billion total in upfront/milestone payments plus tiered royalties on global sales.
  3. Strategic pharma partnership economics: Aditum Bio negotiates strategic deals with global pharma partners for regional development and commercialization rights to assets advanced through portfolio companies — e.g., the Clavis Bio five-year collaboration with Fosun Pharma provides potential payments to Fosun of up to $362.50 million plus milestones and royalties, with Aditum launching additional subsidiaries for any programs Clavis advances.

Pricing tiers

ModelBillingPrice
Other—Fund I — Launched 2019 (closed at $133M); Fund II — Launched 2021; Fund III — Launched 2024 (currently deploying). Fund sizes and LP terms not publicly disclosed.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Aditum Bio product offering

Product offering

Core offering

Aditum Bio is a biotech venture capital firm that identifies, in-licenses, and acquires clinic-ready or translational-stage drug candidates from large pharmaceutical companies, then spins out dedicated portfolio companies under the Aditum umbrella to advance each candidate through Phase 1 and Phase 2 clinical trials. The firm operates through successive venture funds (Fund I launched 2019, Fund II launched 2021, Fund III launched 2024) and has launched 13 portfolio companies targeting underserved disease areas including obesity, depression, substance use disorders, renal disease, infectious diseases, autoimmune and cardiovascular disorders.

Differentiator

Problem solved

Functional benefit

Products and services

  • Aditum Bio Fund I
  • Aditum Bio Fund II
  • Aditum Bio Fund III
  • Aditum Bio Biotech Venture Capital Platform

Quantifiable outcome

  • 13 portfolio companies launched since 2019
  • +11 more outcomes

Companies that use Aditum Bio

Customer profile

Segments4 records

Ideal customer profiles3 records

Aditum Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aditum Bio partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered flagship regional partnership, flagship / core portfolio partnership, major portfolio asset licensor, major exit / strategic acquirer, foundational / repeated asset licensor, core operating partner and founding team member (advisory).

  • Fosun Pharma (Shanghai-based)flagship regional partnershipStrategic or Co-development Partner · 19 December 2025Five-year collaboration with newly launched portfolio company Clavis Bio: Fosun holds exclusive rights to develop, manufacture and commercialize partnered assets in China, Hong Kong and Macau, while Clavis Bio can license programs elsewhere. Potential payments to Fosun of up to $362.50 million plus milestones and royalties. Aditum will launch additional subsidiaries for any programs Clavis advances, with Fosun receiving a minority stake in these new companies.
  • Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH)flagship / core portfolio partnershipStrategic or Co-development Partner · 17 September 2025Exclusive global license agreement in conjunction with formation of Kalexo Bio (portfolio company) to develop 2MW7141, a novel dual-target siRNA candidate for lipid management in dyslipidemia and prevention of high-risk atherosclerotic cardiovascular disease (ASCVD) events. Mabwell granted exclusive worldwide rights to develop, manufacture, and commercialize 2MW7141; Mabwell is eligible for up to USD $1 billion total in upfront and milestone payments plus tiered royalties on global sales, including $12 million in non-refundable upfront and near-term cash payments and an equity stake in Kalexo Bio. Aditum Bio will provide funding for Kalexo Bio.
  • Leads Biolabs (Nanjing Leads Biolabs Co., Ltd.)flagship / core portfolio partnershipStrategic or Co-development Partner · 7 November 2024Strategic asset licensing and co-development partnership: Leads Biolabs granted Oblenio Bio (an Aditum Bio portfolio company, the thirteenth launched) an exclusive option to develop, manufacture, and commercialize LBL-051, a first-in-class CD19×BCMA×CD3 tri-specific T-cell engager antibody for autoimmune diseases, worldwide. Leads Biolabs is eligible for up to $35M in upfront and near-term payments plus $579M in development, regulatory, and commercialization milestone payments, royalties on sales, and an equity stake in Oblenio Bio. The compound was discovered using Leads Biolabs' proprietary LeadsBody™ platform. In June 2026 Oblenio closed a $62M oversubscribed Series B led by Pfizer Ventures with Aditum participation to advance LBL-051 into clinical development.
  • Inmagene Biopharmaceuticalsmajor portfolio asset licensorStrategic or Co-development Partner · 21 September 2023Asset in-licensing partnership in conjunction with formation of Celexor Bio (tenth Aditum Bio company): Inmagene licensed IMG-018, a depleting antibody targeting immunoglobulin-like transcript 7 (ILT7) on plasmacytoid dendritic cells (pDCs), renamed CLXR-901, for autoimmune and inflammatory disorders.
  • Eli Lilly and Company (NYSE: LLY)major exit / strategic acquirerStrategic or Co-development Partner · 14 August 2023Strategic acquirer of Versanis Bio (portfolio company founded/seeded by Aditum Bio) for up to $1.925 billion in cash, inclusive of upfront payment and subsequent milestone payments, expanding Lilly's cardiometabolic portfolio to include bimagrumab.
  • Daewoong Pharmaceutical Co., Ltd.major portfolio asset licensorStrategic or Co-development Partner · 27 April 2023Asset in-licensing partnership in conjunction with formation of Vitalli Bio (ninth Aditum Bio company): Daewoong licensed a highly selective dual inhibitor of Interleukin-2-Inducible T-Cell Kinase (ITK) and Bruton's Tyrosine Kinase (BTK), renamed VIT-801, anticipated to enter Phase 1 studies in 2023. Vitalli Bio also granted an option to license earlier stage dual-target inhibitors in development by Daewoong.
  • Motorpharma, Ltd. (Hungary)major portfolio asset licensorStrategic or Co-development Partner · 15 November 2021Asset in-licensing partnership in conjunction with formation of Motric Bio (seventh Aditum Bio company): Motorpharma licensed a myosin-2 inhibitor that has shown selective inhibition of fast skeletal muscle, to develop a therapy for spasticity associated with neurological injuries and disease (stroke, multiple sclerosis, etc.). Motorpharma is a spin-off of Eötvös Loránd University, Hungary.
  • Novartis (multiple asset in-licensing transactions)foundational / repeated asset licensorStrategic or Co-development Partner · 7 September 2021Recurring asset licensing counterparty: Via Nova Therapeutics was founded in August 2021 following the in-licensing of four preclinical antiviral programs (influenza A, human rhinovirus, BK polyomavirus, adenovirus) from Novartis. Aditum Bio also licensed bimagrumab from Novartis (the foundation for Versanis Bio, sold to Eli Lilly for up to $1.925B in August 2023). Additional portfolio asset licensors include Celexor Bio/Inmagene (co-developing IMG-020 izokibep).
  • Taisho Pharmaceutical Co., Ltd.major portfolio asset licensorStrategic or Co-development Partner · 30 June 2021Asset licensing partnership: Taisho Pharmaceutical in-licensed ANC-501, a selective vasopressin 1b receptor (V1b) antagonist, to Aditum Bio's portfolio company Ancora Bio (later renamed EmbarkNeuro) for the treatment of treatment-resistant depression. The asset is a Phase II-ready, first-in-class V1b receptor antagonist that entered Phase 2 trials in November 2022.
  • TrialSparkcore operating partnerTechnology or Integration · 30 June 2021Technology-driven clinical trial execution partner: TrialSpark operates as an alternative to traditional CROs, with a digital platform that optimizes all aspects of a clinical trial, enabling faster trial completion, higher data quality, and a more patient-centric experience. Aditum Bio uses TrialSpark to complete clinical trials faster and at lower cost than traditional trials; TrialSpark partners with doctors in community settings to create trial and referral sites within their existing practices, accelerating recruitment rates.
  • vTv Therapeutics (NASDAQ:VTVT)major portfolio asset licensorStrategic or Co-development Partner · 15 December 2020Asset in-licensing partnership in conjunction with formation of Anteris Bio (third Aditum Bio company): vTv Therapeutics licensed ANT-401, a small molecule activator of Nrf2 (via Bach1 inhibition), for the treatment of renal disease.
  • Sosei Heptares (4565:JP)major portfolio asset licensorStrategic or Co-development Partner · 2 November 2020Asset licensing partnership: TMP-301 (mGluR5 negative allosteric modulator for substance use disorders and anxiety) was in-licensed from Sosei Heptares to form Tempero Bio, Aditum's second portfolio company. Sosei Heptares is Japan-listed; its StaR®/SBDD platform underpins the asset. Tempero Bio subsequently received FDA IND clearance (Jan 2023) and a $5.3M NIDA grant, and closed a $70M Series B in March 2025.
  • Paul Sekhri (co-founder, eGenesis Inc.)founding team member (advisory)Strategic or Co-development Partner · 1 January 2019Co-founder of Aditum Bio alongside Joe Jimenez and Mark Fishman; President and CEO of eGenesis Inc., who remained at eGenesis but contributed to the formation of the firm in 2019.

Scale indicators15 records

Recent moves17 records

Expansion highlights5 records

Aditum Bio competitors and assessment

Company assessment

Direct peers

  • BridgeBio Pharma: BridgeBio is an asset-centric biotech that licenses and develops genetically validated therapies across multiple therapeutic areas, similarly spinning out focused subsidiaries. The 'asset-first, company-second' operating philosophy closely mirrors Aditum's incubator approach.
  • Atlas Venture: Atlas Venture is a leading early-stage biotech VC firm that co-led the $70M Series A for Aditum's Versanis Bio. It is a direct strategic peer with a comparable company-creation approach focused on building therapeutic-area-focused biotechs from inception.
  • Forbion: Forbion is a leading European biotech VC with a strong company-creation and late-stage growth practice. It is comparable to Aditum in deploying capital into translational-stage biotechs and building dedicated companies around de-risked assets.
  • Medicxi: Medicxi is a European asset-centric biotech VC firm that co-led the $70M Series A for Aditum's Versanis Bio. It is one of the most direct strategic peers in the asset-centric biotech VC space, with comparable fund sizes and a similar translational-stage focus.
  • Roivant Sciences: Roivant operates a near-identical 'Vant' model of in-licensing deprioritized pharma assets and spinning out dedicated subsidiaries to advance them. Both firms use translational-stage sourcing, dedicated portfolio companies, and shared in-house operating infrastructure, making Roivant the closest public-market comparable to Aditum's spin-out model.
  • Cydan Development: Cydan is an asset-creation biotech incubator that identifies promising therapeutic assets and spins out dedicated companies to develop them, mirroring Aditum's model with a sharper focus on rare diseases. Operates a near-identical in-license-and-spin-out framework.

Broad incumbents

  • Khosla Ventures: Khosla Ventures is a large generalist VC firm with a significant biotech practice that co-invested in Aditum's Tempero Bio ($70M Series B in March 2025). It is a broader incumbent in the biotech VC space with adjacent translational-stage exposure.
  • ARCH Venture Partners: ARCH is a large, established biotech VC firm with a long track record in company formation. It represents a broader incumbent peer in the translational-stage biotech VC space, though with a wider therapeutic-area mandate and significantly larger AUM.
  • OrbiMed Advisors: OrbiMed is one of the largest healthcare-dedicated investment firms globally, with broad public and private biotech exposure. It is a broader incumbent in the biotech VC space, offering partial overlap with Aditum's translational-stage deployment model but at materially greater AUM scale.

Emerging players

  • Curie.Bio: Curie.Bio is a newer biotech VC firm offering 'founder-friendly' asset incubation, with overlap in translational-stage deal sourcing and shared operating infrastructure. It represents a more recent entrant with a similar company-creation model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Aditum Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aditum Bio leadership team

Management profile

Number of profiles

Profiles15 records

Aditum Bio subsidiaries and ownership

Company hierarchy

Subsidiaries12 records

Aditum Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aditum Bio M&A and investment

M&A and investment

M&A1 record

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aditum Bio

What does Aditum Bio do?

Aditum Bio is a biotech venture capital firm that identifies, in-licenses, and acquires clinic-ready or translational-stage drug candidates from large pharmaceutical companies, then spins out dedicated portfolio companies under the Aditum umbrella to advance each candidate through Phase 1 and Phase 2 clinical trials. The firm operates through successive venture funds (Fund I launched 2019, Fund II launched 2021, Fund III launched 2024) and has launched 13 portfolio companies targeting underserved disease areas including obesity, depression, substance use disorders, renal disease, infectious diseases, autoimmune and cardiovascular disorders.

Is Aditum Bio a public or private company?

Aditum Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Aditum Bio founded?

Aditum Bio was founded in 2019. It employs 51 to 100 people.

Where is Aditum Bio based?

Aditum Bio is headquartered in Oakland, United States, in the North America region.

How does Aditum Bio make money?

Three revenue lines are on record. Biotech venture capital fund returns (Fund I, Fund II, Fund III) is the primary driver. The others are licensing royalties and milestones from portfolio companies and strategic pharma partnership economics.

Who are Aditum Bio's main competitors?

Direct peers on record are BridgeBio Pharma, Atlas Venture, Forbion, Medicxi, Roivant Sciences and Cydan Development. Broad incumbents are Khosla Ventures, ARCH Venture Partners and OrbiMed Advisors. Curie.Bio is listed as an emerging player.

Does Aditum Bio have an API?

No public API is recorded for Aditum Bio.

What industry is Aditum Bio in?

Aditum Bio's product category is Biotech Venture Capital. Its primary akta.pro industry code is FSANAHAK, Corporate Fintech / Insurtech CVC (Financial-services-led CVC). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineOblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical DevelopmentOblenio Bio closed a $62 million Series B round led by Pfizer Ventures, with participation from Deep Track Capital, GV, and Aditum Bio. The funds will advance LBL-051, a tri-specific T-cell engager, into clinical development, with a first-in-human proof-of-concept study planned this year.BioSpaceLeads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical DevelopmentOblenio Bio closed an oversubscribed $62 million Series B financing led by Pfizer Ventures to advance LBL-051, a tri-specific T-cell engager for autoimmune diseases. Preclinical data showed complete B-cell and plasma cell depletion in non-human primates without cytokine release syndrome. The company plans to move rapidly toward clinical trial initiation.BioSpaceOblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical DevelopmentOblenio Bio closed a $62 million Series B round led by Pfizer Ventures, with participation from Deep Track Capital, GV, and Aditum Bio. The funds will advance LBL-051, a tri-specific T-cell engager, into clinical development, with a first-in-human proof-of-concept study planned this year. Preclinical data presented at EULAR 2026 showed safe B-cell and plasma cell depletion without cytokine release syndrome.FinSMEsOblenio Bio Closes $62M Series B FundingOblenio Bio raised $62M in Series B funding led by Pfizer Ventures, with participation from Deep Track Capital and GV. The company will use the funds for initial clinical development of its tri-specific T-cell engager LBL-051, designed to treat refractory autoimmune diseases.FierceBiotechVC Aditum Bio launches new biotech in business play with Fosun PharmaVenture capital firm Aditum Bio has launched a new biotech subsidiary, Clavis Bio, in partnership with Shanghai-based Fosun Pharma for a five-year collaboration to develop novel therapies. Under the deal, Fosun will hold exclusive rights to develop, manufacture and commercialize partnered assets in China, Hong Kong and Macau, while Clavis can license programs elsewhere, with potential payments to Fosun of up to $362.50 million plus milestones and royalties. Aditum will launch additional subsidiaries for any programs Clavis advances, with Fosun receiving a minority stake in these new companies.PR NewswireMabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular DisordersMabwell (Shanghai) Bioscience and Aditum Bio announced the formation of Kalexo Bio, a new company, along with an exclusive global license agreement to develop 2MW7141, a novel dual-target siRNA therapy for lipid management and prevention of atherosclerotic cardiovascular disease events. Under the agreement, Mabwell will grant Kalexo Bio exclusive worldwide rights to develop, manufacture, and commercialize the therapy, with Mabwell eligible to receive up to USD $1 billion in upfront and milestone payments plus tiered royalties, including $12 million in non-refundable near-term cash payments, along with an equity stake in Kalexo Bio. The partnership leverages Aditum Bio's incubator model to accelerate the therapy into clinical development for patients at high risk of cardiovascular disease worldwide.PR NewswireMabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular DisordersMabwell Bioscience and Aditum Bio have formed Kalexo Bio, a new company dedicated to developing 2MW7141, a novel dual-target siRNA therapy for lipid management in patients with dyslipidemia and prevention of atherosclerotic cardiovascular disease events. Under the exclusive worldwide license agreement, Mabwell grants Kalexo Bio rights to develop, manufacture, and commercialize the therapy, eligible to receive up to $1 billion in upfront and milestone payments plus tiered royalties, including $12 million in non-refundable near-term cash payments. The therapy demonstrated potent and sustained gene suppression in preclinical studies with low risk of off-target effects, and Aditum Bio will provide funding through its incubator model to advance the candidate into clinical development.PR NewswireAditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune DisordersAditum Bio and Leads Biolabs formed Oblenio Bio to develop LBL-051, a tri-specific T-cell engager for autoimmune diseases. Leads Biolabs will grant an exclusive option, with up to $35 million upfront and $579 million in milestone payments. The partnership aims to bring the therapy into clinical studies.PR NewswireInmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion functionInmagene Biopharmaceuticals has partnered with Aditum Bio to form Celexor Bio, a new biotech company dedicated to developing IMG-018 (renamed CLXR-901), a monoclonal antibody that targets and depletes plasmacytoid dendritic cells for autoimmune and inflammatory disorders. Celexor will obtain exclusive global rights to develop, manufacture, and commercialize the therapy in a transaction expected to close later this month. Inmagene will receive an upfront fee, up to $287 million in development and sales milestone payments, royalties on future product sales, and an equity stake in Celexor Bio.PR NewswireAditum Bio Announces Formation of Celexor Bio, Focused on Cell Depletion of Pathologic Cells in Autoimmune and Inflammatory DisordersAditum Bio, a biotech investment firm co-founded by former Novartis executives, has announced the formation of Celexor Bio as its tenth portfolio company to develop novel therapies for autoimmune and inflammatory disorders. Celexor Bio is licensing a depleting antibody (CLXR-901, formerly IMG-018) from Inmagene Biopharmaceuticals that targets and depletes pathological plasmacytoid dendritic cells implicated in inflammatory diseases. The therapy aims to offer a potentially safe and effective alternative for patients with severe autoimmune and inflammatory conditions by directly depleting the cells driving the disease pathophysiology.